<DOC>
	<DOCNO>NCT00954889</DOCNO>
	<brief_summary>The purpose study explore efficacy safety tamsulosin 0.4mg ( Harnal® D. 0.2mg , 2T ) patient LUTS/BPH refractory tamsulosin 0.2mg ( Harnal® D 0.2mg , 1T ) .</brief_summary>
	<brief_title>Clinical Effect Safety Tamsulosin 0.4mg Patients With LUTS/BPH Refractory Tamsulosin 0.2mg</brief_title>
	<detailed_description>Alpha-adrenoreceptor antagonist become primary medical treatment low urinary tract symptom ( LUTS ) associate benign prostatic hyperplasia ( BPH ) . The next treatment method trans-urethral resection prostate ( TURP ) . TURP efficient BPH treatment relieve symptom improve uroflow , also invasive morbid . Tamsulosin high selectivity pharmacological a1-adrenoceptor subtype clone a1a subtype a1b subtype . Tamsulosin 0.4 mg improve Qmax slightly great extent alfuzosin 10 mg. ( 26 % 16 % versus baseline , respectively ) ( http : //www . fda.gov/cder/approval/ index.htm ; access October 27 , 2003 . ) Tamsulosin 0.4 mg o.d . report well tolerated irrespective age and/or cardiovascular comorbidity/co-medication ( Michel et al 1998 ) interaction several antihypertensive agent report . ( Lowe et al . 1997 ) Our study explore efficacy safety tamsulosin 0.4mg ( Harnal® D. 0.2mg , 2T ) patient LUTS/BPH refractory tamsulosin 0.2mg ( Harnal® D 0.2mg , 1T ) .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Male ≥ 45years ( LUTS/BPH patient refractory tamsulosin 0.2mg 4 week ) *All follow : Moderate severe LUTS : IPSS ≥ 13 An enlarged prostate ( ≥ 20mL , moderately enlarge ) Decreased peak flow rate : Qmax ≥4ml/s , ≤15mL/s volume void ≥ 125 mL ) Post void residual urine ≥ 200mL Patients perform catheterization Urinary tract infection patient Patients take 5 alpha reductase inhibitor Known hypersensitivity tamsulosin History postural hypotension syncope Hypertension patient treat alpha1blockers Patients newly take anticholinergic medication within 1 month Hepatic insufficiency ( AST/ALT ≥ 2 time normal range ) Renal insufficiency ( sCr ≥ 2mg/dL )</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>